绥美凯对艾滋病有多大效果？

For adults and adolescents, the recommended dose is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. Today we will find out how effective Suimeikai is against AIDS?

Inbec is a drug for the treatment of AIDS. Inbec is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

Suimeikai has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance. 

Suimeikai is a core drug based on DTG, an integrase inhibitor. In the real world, antiviral treatment-naïve patients treated with DTG are better than RAL (Ascent), DRV/r (darunavir), and EFV (efavirenz). ) and ATV/r (atazanavir) have a lower proportion of central nervous system-related (CNS) adverse events. Therefore, the drug safety of Trimeq, which is based on DTG integrase inhibitors, has proven to be controllable. 

Clinical safety data for Trimax are limited. The most commonly reported adverse reactions thought to be possibly or probably related to dolutegravir and abacavir/lamivudine (pooled data from 679 antiretroviral-naïve subjects who received this combination in phase IIb to IIIb clinical trials) were nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).

The above is the content on the effect on AIDS, I hope it can help you!